Every material Form 8-K Chemours filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chemours reported third quarter 2025 net sales of $1.5 billion, flat year over year, and net income attributable to Chemours of $60 million, or $0.40 per diluted share, compared with a net loss of $32 million a year earlier. Adjusted net income fell to $30 million, or $0.20 per diluted share, from $61 million, and adjusted EBITDA declined to $195 million from $202 million. For fourth quarter 2025, the company expects adjusted EBITDA of $130 million to $160 million on sequentially lower net sales, which would be below the third quarter level.
Net sales of $1,495 million, down 1% from $1,508 million in Q3 2024; Thermal & Specialized Solutions sales rose 20% to $560 million
Net income attributable to Chemours of $60 million ($0.40 per diluted share) vs. a net loss of $32 million ($0.22) in Q3 2024; adjusted net income of $30 million ($0.20 per share) vs. $61 million ($0.40)
Fourth quarter 2025 outlook: net sales expected to fall 10% to 15% sequentially; adjusted EBITDA expected between $130 million and $160 million
Liquidity of $1.6 billion at September 30, 2025, including $613 million in unrestricted cash; net leverage ratio of approximately 4.6x
Chemours adopted an Executive Severance Policy on October 28, 2025, covering executive officers and certain designated employees. Under the policy, a CEO terminated without cause or resigning for good reason would receive 2.0 times the sum of base salary, target annual incentive and annualized health care subsidy, while other participants would receive 1.0 times that sum. The policy sets severance terms for participants but does not change existing change-in-control agreements or outstanding equity awards, so its effect on shareholders depends on how many people are designated and when terminations occur.
Policy adopted by the Board on October 28, 2025, effective the same day.
CEO cash severance: 2.0 times base salary, target annual incentive and annualized health care subsidy.
Other executive officers and employees: 1.0 times the same sum.
Participants must sign a release of claims; existing change-in-control agreements and equity awards are not superseded.
Chemours amended its credit agreement on October 15, 2025, extending the maturity of its $1,050,000,000 senior secured Term Loan B-3 US$ Facility from August 18, 2028 to October 15, 2032, with a new margin of Term SOFR + 3.50% or base rate plus 2.50%. Separately, Chemours subsidiaries agreed to sell up to €180 million of eligible receivables to BNP Paribas Factor GmbH under a Receivables Purchase Agreement, and Chemours accepted joint and several liability for the subsidiaries' obligations under it.
Term Loan B-3 US$ Facility of $1,050,000,000 extended from August 18, 2028 to October 15, 2032
Margin set at Term SOFR + 3.50% or adjusted base rate plus 2.50%, at the Company's election
Receivables sales of up to €180 million to BNP Paribas Factor GmbH; initial term through October 14, 2026, with automatic one-year extension
Chemours accceded to joint and several liability for the Chemours Sellers' obligations on October 14, 2025
Chemours Chair Dawn Farrell notified the board on August 29, 2025, that she will resign effective September 2, 2025, to become CEO of Canada's newly created Major Projects Office. The board has not yet chosen a successor as chair and said an announcement will follow, so shareholders will be watching for who leads the board.
Dawn Farrell resigns as Chair and from the Board effective September 2, 2025
Farrell is accepting appointment as CEO of the Major Projects Office launched by the Prime Minister of Canada under the Building Canada Act
No successor as Board Chair has been named; the company says an announcement will be forthcoming
Chemours reported second quarter 2025 net sales of $1.6 billion, up 4% from a year earlier, but swung to a net loss of $381 million, or $2.54 per diluted share, from net income of $60 million a year earlier. The company said the loss was driven mainly by litigation charges tied to its New Jersey PFAS settlement, while adjusted net income rose to $87 million, or $0.58 per share.
Net sales were $1.6 billion, up 4% from $1,554 million in Q2 2024
Net loss attributable to Chemours was $381 million, or $2.54 per diluted share, versus net income of $60 million, or $0.39, in Q2 2024
Adjusted net income was $87 million, or $0.58 per diluted share, versus $58 million, or $0.38, a year earlier
Full-year 2025 Adjusted EBITDA is expected to be $775 million to $825 million, and Q3 2025 Adjusted EBITDA $175 million to $195 million
Chemours, DuPont and Corteva agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve pending environmental claims, including statewide PFAS claims. Chemours will pay 50% of the $875 million settlement over 25 years, about $250 million on a present value basis, and the settlement remains subject to notice, comment and court approval. Chemours also agreed to sell its rights to $150 million of potential PFAS insurance proceeds to DuPont and Corteva, which it expects to fully fund its settlement payments through at least 2030.
Settlement totals $875 million over 25 years, with pre-tax present value of about $500 million; payments begin no earlier than January 1, 2026
Chemours responsible for 50% of settlement payments, about $250 million on a present value basis
DuPont and Corteva to purchase Chemours' rights to $150 million of PFAS insurance proceeds, contingent on JCO approval
Settlement remains subject to notice and comment under New Jersey law and final court approval
Chemours reported a first-quarter 2025 net loss of $4 million, or $0.03 per diluted share, compared with net income of $54 million a year earlier. Adjusted EBITDA fell 13% to $166 million, mainly on lower pricing, and the company cut its quarterly dividend 65% to $0.0875 per share. For shareholders, the lower dividend reduces cash returned to them, and the company's 2025 adjusted EBITDA outlook of $825 million to $950 million is the main guide to near-term earnings.
Net sales were $1.4 billion ($1,368 million), flat year over year; net loss was $4 million versus net income of $54 million in Q1 2024.
Adjusted net income was $19 million, or $0.13 per diluted share, versus $47 million, or $0.31, a year earlier.
Restructuring charges of $27 million were tied to the exit of the SPS Capstone business, which the company expects to end by the end of the second quarter of 2025.
Quarterly dividend cut 65% to $0.0875 per share for the second quarter, payable June 16, 2025; full-year 2025 adjusted EBITDA outlook is $825 million to $950 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Chemours filing is on SEC EDGAR ↗. 8-K briefs of other companies →